Study of Omalizumab in Moderate to Severe Bronchial Asthma

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Collaborator: Daiichi Sankyo Co., Ltd.
• Treatments: Omalizumab

Criteria

Inclusion Criteria:

• Allergic asthma patients

• Inadequately controlled patients

Exclusion Criteria:

• - History of severe anaphylactoid or anaphylactic reactions

• Previous treatment with omalizumab

• History of cancer or cancer

Other protocol-defined exclusion criteria may apply